Sanofi

News

A COVID jab held in hands wearing surgical gloves

FDA approves new COVID shots - with same restrictions as las...

FDA has approved the 2026 COVID vaccine formulations, but last year's narrower recommendation stands, leaving open questions about access.

News

Sanofi to lay off 229 Blueprint employees, close offices

A year after its $9.1bn acquisition of Blueprint Medicines, Sanofi is moving out of Blueprint's Cambridge, MA offices and letting 229 employees go.

News

Sanofi drops two more programmes in R&D clear-out

Shortly after terminating one late-stage R&D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.

News

Sanofi gives up on amlitelimab in atopic dermatitis

Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.

News

EU seeks advice on Sanofi's response to mismarketing claim

The EU is asking for feedback on measures proposed by Sanofi to address concerns about an allegedly misleading marketing campaign for a flu vaccine.

News

Sanofi eyes extending Nexviazyme into infantile Pompe

Armed with new phase 3 data, Sanofi will try to expand the US label of its Pompe disease drug Nexviazyme to include the severe infantile-onset form.

FDA approves new COVID shots - with same restrictions as las...

Sanofi to lay off 229 Blueprint employees, close offices

Sanofi drops two more programmes in R&D clear-out

Sanofi gives up on amlitelimab in atopic dermatitis

EU seeks advice on Sanofi's response to mismarketing claim

Sanofi eyes extending Nexviazyme into infantile Pompe

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Sanofi

Editor's Picks